CART-ddBCMA for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Multiple MyelomaCART-ddBCMA - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment that uses a patient's own immune cells to target and destroy cancer cells.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Study Objectives

2 Primary · 21 Secondary · Reporting Duration: 24 months

24 Months
Anti-CART-ddBCMA Antibodies
Define the Pharmacokinetics of CART-ddBCMA
Duration of Response (DoR)
Health Related Quality of Life (HRQoL)
Overall Response Rate (ORR)
Overall Response Rate (ORR) of subjects limited to three lines of prior treatment
Overall Survival (OS)
Progression Free Survival (PFS)
Safety Profile of CART-ddBCMA
Stringent complete response (sCR) or complete response (CR) rate
Very Good Partial Response (VGPR) Rate and Partial Response (PR) Rate
24 months
Adverse Event Collection
Anti-CART-ddBCMA antibodies
Health Related Qualify of Life (HRQoL)
Length of Disease Response
Length of Time to First Disease Response
Minimal Residual Disease (MRD)
Pharmacokinetics of CART-ddBCMA
Progression Free Survival (PFS) and Overall Survival (OS)
Stringent Complete Response (sCR) or Complete Response (CR) Rate
Subject Response Rate (Overall Response Rate)
Time to Initial Response
Very Good Partial Response (VGPR) or Partial Response (PR) Rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

CART-ddBCMA
1 of 1

Experimental Treatment

110 Total Participants · 1 Treatment Group

Primary Treatment: CART-ddBCMA · No Placebo Group · Phase 2

CART-ddBCMA
Biological
Experimental Group · 1 Intervention: CART-ddBCMA · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

Arcellx, Inc.Lead Sponsor
2 Previous Clinical Trials
89 Total Patients Enrolled
1 Trials studying Multiple Myeloma
65 Patients Enrolled for Multiple Myeloma
Multiple Myeloma Research FoundationOTHER
10 Previous Clinical Trials
7,362 Total Patients Enrolled
10 Trials studying Multiple Myeloma
7,362 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have the capacity to give informed consent.
You have serum free light chain ≥10 mg/dL with abnormal κ/λ ratio (i.e.
You have a performance status of 0 or 1.
You have a life expectancy of more than 12 weeks.
Oxygen saturation ≥92% on room air.